Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?
Cancers · 16.06.2026 · 18 (12) · 1961
DOI: 10.3390/cancers18121961 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.06.2026. Verfasst von Luisa Piccin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To describe the scientific evidence regarding adjuvant treatment for stage III and IV cutaneous melanoma and the unresolved issues in this setting.
Methods
This review examines the main studies on adjuvant medical therapies approved over the years by the Food and Drug Administration and European Medicines Agency together with the main evidence related to the treatments referred to in the National Comprehensive Cancer Network and European Society of Clinical Oncology guidelines at the time of submission (May 2026) for stage III and IV cutaneous melanoma. A particular focus on immunotherapy (interferon, ipilimumab, and anti-PD-1 antibodies, both as monotherapy and in combination) and targeted therapy with anti-BRAF agents, either as monotherapy or in combination with MEK inhibitors, is given. Besides that, this work also evaluates the role of radiation therapy and addresses some unresolved issues, such as adjuvant therapy in stage IIIA and treatment selection in BRAF-mutated melanoma.
Results
Adjuvant therapy for stage III and IV cutaneous melanoma has evolved over the years, starting with interferon and progressing to the use of immunocheckpoint inhibitors and targeted therapy. However, not all treatments that have proven effective in metastatic disease have subsequently played a role in the adjuvant setting.
Conclusions
Currently, adjuvant treatment for stage III and IV cutaneous melanoma involves the use of anti-PD-1 antibodies (nivolumab and pembrolizumab) and dabrafenib plus trametinib if the patient has a BRAF V600 mutation. It was not possible to identify the adjuvant therapy of choice for BRAF-mutated melanoma, and several factors must be considered when deciding between immunotherapy and targeted therapy. The role of radiation therapy remains controversial and could be discussed by the multidisciplinary team as part of the adjuvant strategy in selected patients. Likewise, adjuvant therapy for stage IIIA melanoma should be carefully evaluated in light of the risk–benefit ratio.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35124 Padova, Italy.
- Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy.
- Department of Medical Sciences, University of Turin, 10126 Torino, Italy.
- European Institute of Oncology, IRCCS, 20141 Milano, Italy.
- Department of Oncology, Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy.
ORCID-Profile: Luisa Piccin, Michele Del Vecchio, Andrea Spagnoletti, Paolo Fava, Gabriele Roccuzzo, Carolina Cimminiello, Alessandro Minisini, Jacopo Pigozzo
Zitieren
APA
Piccin, L., Guarneri, V., Del Vecchio, M., Spagnoletti, A., Fava, P., Roccuzzo, G., Cimminiello, C., Papadopoulos, N., Minisini, A., Costa, J., & Pigozzo, J. (2026). Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?. Cancers, 18(12), 1961. https://doi.org/10.3390/cancers18121961
Vancouver
Piccin L, Guarneri V, Del Vecchio M, Spagnoletti A, Fava P, Roccuzzo G, et al. Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?. Cancers. 2026;18(12):1961. doi:10.3390/cancers18121961
BibTeX
@article{Piccin2026,
author = {Piccin, Luisa and Guarneri, Valentina and Del Vecchio, Michele and Spagnoletti, Andrea and Fava, Paolo and Roccuzzo, Gabriele and Cimminiello, Carolina and Papadopoulos, Nikolaos and Minisini, Alessandro and Costa, Jacopo and Pigozzo, Jacopo},
title = {Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1961},
doi = {10.3390/cancers18121961}
}
EUVIMED